Taking scientific advice during a development programme is imperative because being forewarned is forearmed.
Engaging with scientific advice ensures that sponsors can make informed decisions, minimizing uncertainties and optimizing the path to regulatory approval.
Why is scientific advice essential?
- It allows for the early identification and mitigation of risks.
- It enhances the probability of regulatory success.
- It offers opportunities for fee reductions and process efficiencies.
Whether it’s national scientific advice, simultaneous national scientific advice, or via agencies such as SAWP/CHMP, effective scientific advice requires advanced planning and a strategic approach. Engaging with regulators early can provide valuable perspectives based on their experience with similar programmes, offering potential opportunities to strengthen the development pathway.
While feedback may occasionally be challenging, addressing these issues early is far more beneficial than responding reactively during the marketing authorisation application (MAA) process.
For a comprehensive overview of the diverse routes to obtaining scientific advice in the EU and guidance on how to navigate them, download our whitepaper today.
Read Now
Sign up to our monthly newsletter to read this whitepaper now. Our newsletter gives you the latest European and UK regulatory intelligence. We bring you new and interesting approvals; fast-to-market applications, orphan designations; paediatric applications and therapy area-specific news.
You can unsubscribe at any time from the link in the newsletter footer. Read our Privacy Policy here.